| Name | Title | Contact Details |
|---|
Checkerspot is a design-centric materials company enabling ultra-high performance consumer products.
Evelo Therapeutics is the latest breakthrough microbiome company from Flagship VentureLabs, the innovation foundry of Flagship Ventures.
Virobay is focused on the development and commercialization of novel drugs through the utilization of small molecule inhibitors of cysteine proteases, a diverse class of enzyme proteases, for a variety of conditions, including neuropathic pain, autoimmune diseases and fibrosis. The foundation of Virobay's proprietary cathepsin platform and the Virobay management team were spun-out from Celera Genomics, which was then a leader in cathepsin research. Virobay's clinical pipeline currently includes product candidates in neuropathic pain, dermatology, autoimmune disease and fibrosis.
Elevian develops regenerative medicines that target root-cause aging mechanisms. We are a spin out from Harvard, led by a team of serial entrepreneurs and Harvard scientists.